MedPath

Preoperative Corticosteroid Therapy in Neonates Undergoing Cardiopulmonary Bypass

Not Applicable
Completed
Conditions
Congenital Heart Disease
Disorder of Fetus or Newborn
Interventions
Registration Number
NCT00934843
Lead Sponsor
Medical University of South Carolina
Brief Summary

Randomized controlled trial of the use of glucocorticoids to improve the clinical course of neonates post-cardiopulmonary bypass (CPB).

Detailed Description

This study proposes a randomized controlled trial of the use of glucocorticoids to improve the clinical course of neonates post-cardiopulmonary bypass (CPB). The study will focus on neonates for a few reasons. Although their post-CPB clinical course is typically more severe and intensive care unit (ICU) care more prolonged than older children, their modes of morbidity are also well characterized. Further, the high level of severity itself provides a substrate for identifying the positive effects of a particular therapy. Finally, a therapy identified as beneficial has the greatest potential for benefit in this vulnerable population. The well characterized scenario of low cardiac output syndrome (LCOS) will be used as the primary endpoint, while a variety of secondary endpoints will be related to the biochemical anti-inflammatory effects of therapy, ICU care and late neurological outcome.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
77
Inclusion Criteria
  • Neonates Age </= 1 month
  • Scheduled to undergo cardiac surgery involving Cardiopulmonary Bypass (CPB) (reparative or palliative procedures)
  • Inpatient Status at MUSC a minimum of 8 hours prior to planned surgery
Exclusion Criteria
  • Prematurity: </= 36 weeks post gestational age at time of surgery
  • Treatment with steroids, other than inhaled forms, in the two weeks prior to scheduled surgery
  • Participation in research studies involving the evaluation of investigational drugs within 30 days of randomization
  • Suspected infection that would contraindicate steroid use (eg - Herpes)
  • Known hypersensitivity to IVMP or one of its components or other contraindication to steroid therapy (e.g., gastrointestinal bleeding)
  • Preoperative use of mechanical circulatory support or active resuscitation at the time of proposed randomization
  • Inability to begin the pre-operative study drug at least 8 hours prior to surgery

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Single dose steroidmethylprednisolone (IVMP)Neonates with congenital heart disease requiring surgery utilizing a cardiopulmonary bypass (CPB) machine in the first month of life that receive ONE dose intravenous methylprednisolone (IVMP) prior to heart surgery.
Two Dose steroidmethylprednisolone (two doses IVMP)Neonates with congenital heart disease requiring surgery utilizing a cardiopulmonary bypass (CPB) machine in the first month of life that receive TWO doses intravenous methylprednisolone (IVMP) prior to heart surgery.Compare the effects and preoperative and intraoperative IVMP to intraoperative IVMP alone on the inflammatory response to CPB cardiopulmonary bypass. The hypothesis is that neonates treated with preoperative IVMP as well as the standard intraoperative IVMP will have decreased production of pro-inflammatory cytokines.
Primary Outcome Measures
NameTimeMethod
Primary Endpoint: Number of Participants With Low Cardiac Output Syndrome (LCOS) or Death at 36 Hours From Admission to the Intensive Care Unit (ICU) After Surgery.36 hours

The presence of low cardiac output syndrome (LCOS) was defined by the same definition used in the PRIMACORP study (Hoffman TM.et.al. Circulation 2003 107:996-1002). Specifically, if there were clinical signs and symptoms of low cardiac output (e.g., tachycardia, oliguria, cold extremities, cardiac arrest, etc.) which required one or more of the following interventions: mechanical circulatory support, the escalation of existing pharmacological circulatory support to \>100% over baseline, or the initiation of new pharmacological circulatory support.

Secondary Outcome Measures
NameTimeMethod
Inotropic Scoreover the first 36 hours after surgery

The inotropic score was calculated by the equation using drug dosages in micrograms/kg/min, (dopamine+dobutamine) + (milrinonex10) + (epinephrinex100) and recorded hourly upon arrival to the ICUthrough 36 hours postoperatively. The highest score during this timeframe was recorded. This score converts dosages of commonly used inotropic medications into a score. The higher the score the more inotropic medications required. The minimum score would be zero indicating no inotropic medications were used. There is no maximum score.

Number of Participants Who Died Between 36 Hours and 30 Days Following Cardiac Surgeryat 36 hours and 30 days

Number of participants who died of any cause between 36 hours and 30 days following cardiac surgery

Urine Outputover 36 hours

Total urine output in mL over the first 36 hours after cardiac surgery

Total Intake/Output of Fluidover 36 hours

Total amount of all fluids in and out during the first 36 hours postoperatively in mL.

Trial Locations

Locations (1)

Medical University of South Carolina

🇺🇸

Charleston, South Carolina, United States

© Copyright 2025. All Rights Reserved by MedPath